Few drugs have achieved the stardom that semaglutide, marketed in the United States as Ozempic or Wegovy, has today. A synthetic, injectable version of an intestinal hormone, it is the flagship of a new category of drugs initially developed for diabetes that rose to fame in the medical and public arena as an effective weapon against obesity. Semaglutide has proved so successful that its manufacturer, the Danish company Novo Nordisk, is unable to keep up with demand.